Postmarketing Adverse Drug Experience (PADE) Inspections – Part I
Audits in Pharmacovigilance: A commitment to Safety
German Pharmacovigilance Day, Frankfurt am Main, Germany
CONTACT OUR SALES
Stay updated with expert insights, case studies, in-depth white papers, and the latest thought leadership & innovations in clinical safety, pharmacovigilance & medical affairs.
Reference Safety Information in Clinical Trials
The Reference Safety Information (RSI) section of an Investigator’s Brochure (IB) is an important document that can be a subject of audits and regulatory inspections. In this post, I have provided guidance for some common questions regarding the RSI. The Reference Safety Information (RSI) section of an Investigator’s Brochure (IB)…
The Reference Safety Information (RSI) section of an Investigator’s Brochure (IB) is an important document that can be a subject of audits and regulatory inspections. In this post, I have…